Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives (Q33822774)

29 July 2017

1 reference

title

Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives (English)

1 reference

29 July 2017

1 reference

1 reference

E Van Cutsem

1

1 reference

29 July 2017

publication date

1 March 1999

1 reference

European Journal of Cancer

29 July 2017

published in

1 reference

29 July 2017

volume

35 Suppl 1

1 reference

29 July 2017

page(s)

S1-2

1 reference

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

Biomodulation of Fluorouracil in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

Mature results from three large controlled studies with raltitrexed ('Tomudex').

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

Ongoing and unsaid on oxaliplatin: the hope

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

Status of adjuvant therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900040-4

7 January 2021

10.1016/S0959-8049(99)00040-4

Identifiers

DOI

1 reference

29 July 2017

1 reference